- Home
- FLYE vs CANF Comparison
FLYE vs CANF Comparison
Compare FLYE & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- CANF
- Stock Information
- Founded
- FLYE 2018
- CANF 1994
- Country
- FLYE United States
- CANF Israel
- Employees
- FLYE N/A
- CANF N/A
- Industry
- FLYE Aerospace
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- CANF Health Care
- Exchange
- FLYE Nasdaq
- CANF Nasdaq
- Market Cap
- FLYE 91.6M
- CANF 9.6M
- IPO Year
- FLYE 2024
- CANF N/A
- Fundamental
- Price
- FLYE $0.73
- CANF $0.65
- Analyst Decision
- FLYE
- CANF Strong Buy
- Analyst Count
- FLYE 0
- CANF 2
- Target Price
- FLYE N/A
- CANF $14.50
- AVG Volume (30 Days)
- FLYE 1.8M
- CANF 171.1K
- Earning Date
- FLYE 08-19-2025
- CANF 08-26-2025
- Dividend Yield
- FLYE N/A
- CANF N/A
- EPS Growth
- FLYE N/A
- CANF N/A
- EPS
- FLYE N/A
- CANF N/A
- Revenue
- FLYE $22,881,935.00
- CANF $560,000.00
- Revenue This Year
- FLYE N/A
- CANF $461.72
- Revenue Next Year
- FLYE N/A
- CANF N/A
- P/E Ratio
- FLYE N/A
- CANF N/A
- Revenue Growth
- FLYE N/A
- CANF N/A
- 52 Week Low
- FLYE $0.51
- CANF $0.63
- 52 Week High
- FLYE $8.30
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- FLYE 28.78
- CANF 35.47
- Support Level
- FLYE $0.72
- CANF $0.64
- Resistance Level
- FLYE $0.86
- CANF $0.68
- Average True Range (ATR)
- FLYE 0.08
- CANF 0.02
- MACD
- FLYE 0.17
- CANF 0.01
- Stochastic Oscillator
- FLYE 55.36
- CANF 41.25
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).